Hemicrania continua responsive to botulinum toxin type a: a case report

Modar Khalil1, Fayyaz Ahmed

  • 1Department of Neurology, Hull Royal Infirmary, Kingston-upon-Hull, UK.

Headache
|March 29, 2013
PubMed

Insights

Hemicrania continua (HC) is a rare headache disorder. Botulinum toxin type A effectively treated a patient with HC who experienced side effects from indomethacin, offering a new therapeutic option.

Area of Science:

  • Neurology
  • Headache Medicine

Background:

  • Hemicrania continua (HC) is a primary headache disorder.
  • Indomethacin is a diagnostic criterion for HC due to its efficacy.
  • Indomethacin's side effects can limit its use in managing HC.

Observation:

  • A case of a 33-year-old female patient with HC is presented.
  • The patient experienced gastric side effects from indomethacin.
  • Standard pharmacological treatments were ineffective for the patient's HC.

Findings:

  • Botulinum toxin type A injection resulted in complete resolution of the patient's HC symptoms.
  • This suggests a potential alternative treatment for refractory HC cases.

Implications:

  • Botulinum toxin type A may be a viable therapeutic option for patients with Hemicrania continua who cannot tolerate indomethacin.
  • Further research into the neurobiological mechanisms underlying botulinum toxin's efficacy in HC is warranted.
Abstract